<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02239081</url>
  </required_header>
  <id_info>
    <org_study_id>CP730.1001</org_study_id>
    <nct_id>NCT02239081</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of CTP-730 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single center, single-ascending dose, randomized study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a Screening period of up to 21 days, eight (8) subjects in each cohort, 6 subjects
      randomized to CTP-730 and 2 subjects randomized to placebo, will be admitted to the clinical
      research unit (CRU) on the evening before dosing and remain sequestered at the study site
      until after the last inpatient blood sample is collected at 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters</measure>
    <time_frame>96 hours</time_frame>
    <description>Peak plasma concentration - Cmax by dose Area under the plasma concentration by time - AUC by dose</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CTP-730, 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-730, 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Suspension, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-730</intervention_name>
    <arm_group_label>CTP-730, 5 mg</arm_group_label>
    <arm_group_label>CTP-730, 10 mg</arm_group_label>
    <arm_group_label>CTP-730, 20 mg</arm_group_label>
    <arm_group_label>CTP-730, 30 mg</arm_group_label>
    <arm_group_label>CTP-730, 40 mg</arm_group_label>
    <arm_group_label>CTP-730, 50 mg</arm_group_label>
    <arm_group_label>CTP-730, 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for CTP-730</intervention_name>
    <arm_group_label>CTP-730, 5 mg</arm_group_label>
    <arm_group_label>CTP-730, 10 mg</arm_group_label>
    <arm_group_label>CTP-730, 20 mg</arm_group_label>
    <arm_group_label>CTP-730, 30 mg</arm_group_label>
    <arm_group_label>CTP-730, 40 mg</arm_group_label>
    <arm_group_label>CTP-730, 50 mg</arm_group_label>
    <arm_group_label>CTP-730, 60 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteer subjects, 18 to 50 years of age, inclusive.

        Exclusion Criteria:

          -  Current significant medical condition, laboratory abnormality, or psychiatric illness

          -  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions

          -  PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcB / QTcF interval &gt; 450 msec

          -  Elevated liver function tests greater than twice the upper limit of normal

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody

          -  Urinalysis positive for protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use.

          -  Inability to comply with food and beverage restrictions during study participation

          -  Donation or blood collection or acute loss of blood prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginny Braman</last_name>
    <role>Study Director</role>
    <affiliation>Concert Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

